UAE pharmaceutical market set to hit $5.7 billion by 2020

11 October 2016
globaldata-logo-big

The pharmaceutical market in the United Arab Emirates (UAE) is set to grow from just over $3 billion in 2015 to $5.7 billion by 2020, driven by increased healthcare expenditure, mandatory health insurance, and growing medical tourism.

According to research and consulting firm GlobalData’s latest report, the UAE is quickly gaining popularity as a medical tourism destination due to its low costs, English-speaking medical staff, and virtually non-existent queues for treatment. Indeed, the Dubai Health Authority is working to develop the medical tourism sector, aiming to attract 1.3 million medical tourists annually by 2021. The revenue on medical tourism is expected to grow by 13% annually for the next five years.

Another driver of growth is the fact that the UAE generally has a stable political and economic environment, allowing for prosperity. One major initiative of the UAE government is its encouragement of private sector involvement and investment with the ultimate aim of improving healthcare. To this end, the government has established the Dubai Healthcare City and Dubai Science Park, which are special zones that come with 100% tax redemption and foreign ownership.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical